OptimizeRx (OPRX) to Release Quarterly Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX) will likely be announcing its earnings results after the market closes on Wednesday, March 26th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $30.36 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $8.63 on Monday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $14.13. The business’s 50 day moving average is $5.84 and its two-hundred day moving average is $5.92. The company has a market capitalization of $158.97 million, a P/E ratio of -6.49 and a beta of 1.31.

Insider Activity

In other OptimizeRx news, Director James Paul Lang purchased 321,408 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were acquired at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the purchase, the director now directly owns 389,452 shares in the company, valued at approximately $2,959,835.20. This trade represents a 472.35 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 6.10% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on OPRX shares. B. Riley upgraded shares of OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of OptimizeRx in a research note on Tuesday, December 24th. JMP Securities reiterated a “market outperform” rating and set a $8.00 price objective on shares of OptimizeRx in a research note on Thursday, February 6th. Stephens assumed coverage on OptimizeRx in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 target price on the stock. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $6.00 price target (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.06.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.